Withaferin A (Ashwaganda)

1. 2, 3-Dihydro-3β-methoxy Withaferin-A Protects Normal Cells against Stress: Molecular Evidence of Its Potent Cytoprotective Activity
2. 2, 3-Dihydrowithaferin A-3β-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera
3. 3beta-methoxy derivation of Withaferin-a Attenuates its Anticancer potency: Bioinformatics and molecular evidences
4. 5,6-De-epoxy-5-en-7-one-17-hydroxy withaferin A, a new cytotoxic steroid from Withania somnifera L. Dunal leaves
5. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers
6. A novel combination of withaferin A and sulforaphane inhibits epigenetic machinery, cellular viability and induces apoptosis of breast cancer cells
7. A rapid and simple high performance thin layer chromatographic method for simultaneous analysis of β-sitosterol-D-glucoside, gallic acid, withaferin A and withanolide A in Ashvagandharishta
8. A Study on the efficacy of Withaferin-A in reducing oxidative stress against DEN induced hepatocellular carcinoma
9. A validated and densitometric HPTLC method for the quantification of Withaferin-A and Withanolide-A in different plant parts of two morphotypes of Withania somnifera
10. A110 THORACIC CANCERS: PATHOGENESIS AND NOVEL TARGETS: The Use Of Withaferin-A As An Anti-Metastatic Agent In Non-Small Cell Lung Cancer
11. Abstract A10: Withaferin-A, a natural compound inhibits AKT-induced metastatic colorectal cancer
12. Abstract A115: withaferin A downregulates her-2/neu protein expression in human breast cancer cells.
13. Abstract A2-32: Identification of withaferin A as a novel cancer stem cell inhibitor to overcome drug resistance in non-small cell lung carcinoma
14. Abstract A29: Targeting adenylate kinase-4 modulation of HIF-1α: Stability identifies Withaferin-A suppresses lung cancer metastasis
15. Abstract A4: withaferin A induces apoptosis in imatinib-resistant CML cells by repressing the Akt signaling pathway
16. Abstract A48: Ovarian tumor-induced immunosuppression of NK cells and its prevention by dietary supplementation of herbal withaferin A (Ashwagandha).
17. Abstract B41: withaferin A promotes ROS-mediated differentiation of neuroblastoma
18. Abstract B57: A natural plant-derived compound, withaferin A, exploits the stress pathway to induce antitumor immunity.
19. Abstract B84: Withaferin‐A is a novel HSF‐1 inhibitor with potent antitumor effects in melanoma in vivo
20. Abstract C218: Novel therapeutic potential in targeting micro tubules by naturally occurring anti cancer agent withaferin A in human cancers.
21. Abstract LB-113: A novel role of withaferin A as an effective pro-apoptotic receptor agonist (PARA) and insights into the underlying molecular mechanisms
22. Abstract LB-154: Epigenetic silencing of triple-negative breast cancer hallmarks by withaferin A
23. Abstract NTOC-100: OVARIAN TUMOR-ASSOCIATED GRP78 INDUCES IMMUNOSUPPRESSION AND withaferin A (ASHWAGANDHA) ENHANCES ANTI …
24. Abstract P2-09-12: withaferin A-mediated inhibition of breast carcinoma involves concomitant activation of CHOP and Elk1 via ERK/ribosomal S6 kinase (RSK) …
25. Abstract# 3903: Inhibition of human cervical cancer cell growth by withaferin A and potential mechanisms
26. Actin microfilament aggregation induced by withaferin A is mediated by annexin II
27. Activation of signal transducer and activator of transcription 3 fails to confer resistance against withaferin A-induced apoptosis in human breast cancer cells
28. Age related differences in stress-induced neurobehavioral patterns in rats modulated by withaferin-A and other antioxidants
29. Agrobacterium rhizogenes mediated hairy root culture system of Withania somnifera L Dunal for withaferin A production
30. Ameliorative effect of withaferin A on ageing-mediated impairment in the dopamine system and its associated behavior of Wistar Albino Rat
31. An adaptogen: withaferin A ameliorates in vitro and in vivo pulmonary fibrosis by modulating the interplay of fibrotic, matricelluar proteins, and cytokines
32. An analog of withaferin A activates the MAPK and glutathione “stress” pathways and inhibits pancreatic cancer cell proliferation
33. Anti-cancer activity of withaferin A in B-cell lymphoma
34. Anti-cancer Effects and Molecular Mechanisms of withaferin A
35. Anticancer Effects of withaferin A in Head and Neck Squamous Cell Carcinomas through Modulation of Heat Shock Protein Expression
36. Anticancer effects of withaferin A on UP-LN1 carcinoma cells through the inhibition of STAT3 phosphorylation and IFN-γ-mediated induction of metastatic cancer stem …
37. Anti-cancer Mechanisms of the Natural Plant Derived Compound, withaferin A in HER-2/neu Breast Cancer
38. Anti-inflammatory effect of withaferin A on dopaminergic neuron of aged rat.
39. Anti-inflammatory effects of withaferin A in islet transplantation and pancreatitis.
40. Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A
41. Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins
42. Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo
43. Apoptosis induction by ayurvedic medicine constituent withaferin A in human breast cancer cells is mediated by reactive oxygen species-dependent activation of Bak
44. Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I–DNA complex
45. AshwaMAX and withaferin A inhibits gliomas in cellular and murine orthotopic models
46. Assessment of hepatoprotective and nephroprotective potential of withaferin A on bromobenzene-induced injury in Swiss albino mice: possible involvement of …
47. Assessment of the Immune Status in “withaferin A” Treated Rats in Experimental Mammary Carcinogenesis by Flow Cytometry
48. Astaxanthin and withaferin A block paracrine cytokine interactions between UVB-exposed human keratinocytes and human melanocytes via the attenuation of …
49. Autophagy fails to alter withaferin A-mediated lethality in human breast cancer cells
50. Axl is a novel target of withaferin A in the induction of apoptosis and the suppression of invasion
51. Ayurvedic medicine constituent withaferin A causes G2 and M phase cell cycle arrest in human breast cancer cells
52. Barrier protective effects of withaferin A in HMGB1-induced inflammatory responses in both cellular and animal models
53. Biomass production and withaferin A synthesis by Withania somnifera grown in aeroponics and hydroponics
54. Biosynthesis of Withanolides in Acnistus breviflorus Chemical Degradation of 14C-Labelled Jaborosalactone A and withaferin A
55. Biotransformation of withaferin-a by a culture ofArthrobacter simplex
56. Broad-spectrum antitumor properties of withaferin A: a proteomic perspective
57. Carbohydrate and elicitor enhanced withanolide (withaferin A and withanolide A) accumulation in hairy root cultures of Withania somnifera (L.)
58. Characterizing withaferin A as a novel NRF2 inducer: implications for liver disease prevention
59. CHEMICAL PROFILING FOR FEW PLANT METABOLITES (WITHANOLIDE-A AND WITHAFERIN-A) INCLUDING ANTI-CANCER COMPOUNDS IN FOREST SPECIES …
60. Chemistry of withaferin-A: chemo, regio, and stereoselective synthesis of novel spiro-pyrrolizidino-oxindole adducts of withaferin-A via one-pot three-component [3+ 2] …
61. Chemo prevention effect of withaferin A, a natural compound, on mouse models of colorectal carcinogenesis
62. Chemopreventive and chemotherapeutic effect of Withaferin-A on in vivo models of prostate cancer
63. Chemotherapeutic effect of withaferin A in human oral cancer cells
64. CHEMOTHERAPEUTIC EFFICACY OF WITHAFERIN-A IN EXPERIMENTAL HEPATOCELLULAR CARCINOMA
65. Circadian time-dependent chemopreventive potential of withaferin-A in 7, 12-dimethyl-benz [a] anthracene-induced oral carcinogenesis
66. Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells
67. Combination strategies for management of ovarian cancer using doxorubicin and withaferin A
68. Combinatorial withaferin A and Sulforaphane and Their Potential Roles in Breast Cancer Prevention and Therapy
69. Comparison of the Protective Effect of Withaferin-‘A’and Hydrocortisone against CCL~ 4 induced Hepatotoxicity in Rats
70. Concomitant activation of ETS-like transcription factor-1 and Death Receptor-5 via extracellular signal-regulated kinase in withaferin A-mediated inhibition of …
71. Concomitant Inhibition of Cytoprotective Autophagy Augments the Efficacy of withaferin A in Hepatocellular Carcinoma
72. Constituents of Withania somnifera Dun. III. The Side Chain of withaferin A*,1
73. Constituents of Withania somnifera Dun. Part IV. The structure of withaferin A
74. Constituents of Withania somnifera Dun. Part VI. The stereochemistry of withaferin A
75. Constituents of Withania somnifera Dun. Part VII. Rearrangements in withaferin A
76. Constituents of Withania somnifera Dun. Part VIII. A new steroidal lactone, 27-deoxy-14-hydroxy-withaferin A
77. Correction: withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo
78. Cytotoxicity of Ashwagandha Derived withaferin A to Human Cancer Cells: Molecular Insights into the Response of Telomerase Plus and Minus Cell
79. Cytotoxicity of Phytocompounds Cannabigerol (CBG) and withaferin A to SKOV3 Ovarian Cancer Cells
80. Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling …
81. Data from SILAC-based quantitative analysis of lysates from mouse microglial cells treated with withaferin A (WA)
82. DD-03THE NATURALLY OCCURRING STEROID, withaferin A, IN SYNERGISTIC CONCERT WITH HER2/EGFR INHIBITORS ABROGATES PROLIFERATION OF …
83. DDEL-04 AshwaMAX and withaferin A inhibits gliomas in cellular and murine orthotopic models
84. Ddis-15. Synergistic Inhibition Of Glioma Cell Proliferation By withaferin A And Tumor Treating Fields
85. Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to …
86. DETERMINATION OF withaferin A CONTENT OF ROOT, STEM AND LEAF EXTRACTS OF WITHANIA SOMNIFERA (L) DUNAL COLLECTED IN KENYA
87. Determination of Withaferin-A in two Withania Species by RP-HPLC method
88. Development and optimization of hairy root culture systems in Withania somnifera (L.) Dunal for withaferin-Aproduction
89. Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia
90. Development of a new method for identification and estimation of Withania somnifera root, and a method for quantitative analysis of withaferin A in young and old …
91. Development of HPTLC fingerprint by simultaneous estimation of Ashwagandha (withaferin-A) and Glycyrrhiza (18-β-glycyrrhetinic acid) in some polyherbal over the …
92. DEVELOPMENT OF VALIDATED RP-HPLC METHOD FOR THE ESTIMATION OF WITHAFERIN-A IN WITHANIA SOMNIFERA, Its EXTRACT AND POLYHERBAL …
93. Development of withaferin A analogs as probes of angiogenesis
94. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells
95. Differential activities of the two closely related withanolides, withaferin A and Withanone: bioinformatics and experimental evidences
96. Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols
97. Differential effect of withaferin A treatment on activation of Notch1 and Notch2 in human breast cancer cells.
98. Disease subtype independent biomarkers of breast cancer prevention by withaferin A
99. Disease Subtype–Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical withaferin A
100. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin A-induced apoptosis in MCF-7 …
101. DOXIL when combined with withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer
102. Drug carrier for sustained release of withaferin A for pancreatic cancer treatment
103. Dual Elicitation for Improved Production of withaferin A by Cell Suspension Cultures of Withania somnifera
104. Early-stage treatment with withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral …
105. Effect of a radiosensitiser, withaferin A, on the free radical metabolising enzymes of neutrophils, in carcinoma of uterine cervix subjected to radiotherapy
106. Effect of rhizobacterial inoculation on withaferin-a content of ashwagandha (var. Jawahar 20) roots.
107. Effect of withaferin A on A549 cellular proliferation and apoptosis in non-small cell lung cancer
108. Effect of withaferin A on cells in tissue culture
109. Effect of withaferin A on Ehrlich ascites tumor cells. II. Target tumor cell destruction in vivo by immune activation
110. Effect of withaferin A on Ehrlich ascites tumor cells—cytological observations
111. Effect of withaferin A on the development and decay of thermotolerance in B16F1 melanoma: A preliminary study
112. Effect of withaferin, a radiosensitizer, on the erythrocyte antioxid-ants in carcinoma of uterine cervix
113. Effects of dietary compounds sulforaphane and withaferin A on MCF-7 breast cancer cells
114. Effects of withaferin A on Mouse Models of Alexander Disease
115. Efficacy of Withania somnifera chemotypes NMITLI – 101R, 118R and withaferin A against experimental visceral leishmaniasis
116. Elicitation of withaferin-A in hairy root culture of Withania somnifera (L.) Dunal using natural polysaccharides
117. Elucidating Anticancer Activity of withaferin A, Major Constituent of Withania somnifera Through Suppression of NF-кB, a Prominent Marker in Cancer
118. Elucidation of molecular mechanism of butyrate and withaferin A induced antiangiogenesis and apoptosis
119. Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells
120. Enhanced activity of chemotherapeutic drugs by blueberry anthocyanidins and withaferin A against human lung cancer cells.
121. Enhanced bioproduction of withaferin A from suspension cultures of Withania somnifera.
122. Enhanced production of withaferin-A in shoot cultures of Withania somnifera (L) Dunal
123. Enhancement of radiation induced cell death in chicken B lymphocytes by withaferin A
124. Enhancement of the response of B16F1 melanoma to fractionated radiotherapy and prolongation of survival by withaferin A and/or hyperthermia
125. Epigenetic silencing of triple negative breast cancer hallmarks by withaferin A
126. ERBB2 overexpression establishes ERBB3-dependent hypersensitivity of breast cancer cells to withaferin A
127. ET-71 the antitumor effects of withaferin A in glioblastoma stem cells
128. Evaluation of analgesic, antipyretic and ulcerogenic effect of withaferin A
129. EVALUATION OF IN VITRO withaferin A PRODUCTION FROM WITHANIA COAGULANS (STOCKS) DUNAL
130. EVALUATION OF withaferin A CONTENT IN DIFFERENT ACCESSIONS AND IN IN VITRO CULTURES OF WITHANIA COAGULANS (STOCKS) DUNAL
131. Evaluation of withaferin A content in different accessions and in in vitro cultures of Withania coagulans (Stocks) Dunal.
132. Evaluation of withaferin-A and analogues as antibacterial agents: Structure-activity relationship study
133. Examination of the effect of the natural plant extract, withaferin A, on heat shock protein gene expression in Xenopus laevis A6 cells
134. Examination of the effect of withaferin A on heat shock protein gene expression in Xenopus laevis A6 kidney epithelial cells
135. Expanding the Chemical Space of withaferin A by Incorporating Silicon to Improve its Clinical Potential on Human Ovarian Carcinoma Cells
136. Exploring the inhibitory activity of Withaferin-A against Pteridine reductase-1 of L. donovani
137. Extraction and Isolation of withaferin A (Steroidal Lactone) from Withania Somnifera Leafs and it’s TLC and HPLC Analysis.
138. Extraction Optimization for Phenolic- and Withanolide-Rich Fractions from Withania somnifera Roots: Identification and Quantification of withaferin A, 12-Deoxywithastromonolide, and Withanolide A in Plant Materials and Marketed Formulations Using a Reversed-Phase HPLC–Photodiode Array Detection Method
139. FORMULATION AND EVALUATION OF SELF-NANO EMULSIFYING DRUG DELIVERY SYSTEM FOR SOLUBILITY AND BIOAVAILABILITY ENHANCEMENT OF POORLY WATER SOLUBLE withaferin A
140. Genetic and withaferin A Analysis of Iranian Natural Populations of Withania Somnifera and W. Coagulans by RAPD and HPTLC
141. Glucose metabolism‐targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor‐induced drug‐tolerant persisters
142. Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of β …
143. Growth inhibitory effects of withaferin A on MDS-L cells–A human 5q Myelodysplastic Syndrome (MDS) cell line
144. High performance thin layer chromatography method for simultaneous estimation of vicine, trigonelline and withaferin A in a polyherbal antidiabetic formulation
145. Homology modelling, molecular docking, and molecular dynamics simulations reveal the inhibition of Leishmania donovani dihydrofolate reductase-thymidylate synthase enzyme by Withaferin-A
146. HPLC analysis of withaferin A in Withania somnifera (L.) Dunal
147. HPTLC method for analysis of withaferin-A in Ashwagandha (Withania somnifera)
148. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug withaferin A
149. Hypothalamic ATP Has a Crucial Role in the Pathogenesis of Leptin Resistance: A Potential Mechanism for the Amelioration of Leptin Resistance by Celastrol and withaferin A
150. Identification and quantitative analysis of cellular proteins affected by treatment with withaferin A using a SILAC-based proteomics approach
151. Identification of Biological Targets of the Angiogenic Agent withaferin A
152. Identification of withaferin A as a potential candidate for anti-cancer therapy in non-small cell lung cancer
153. Imaging withaferin A-Vimentin Interactions in Live Cells and Fibrotic Tissues
154. Immunosuppressive activity of two plant steroidal lactones withaferin A and withanolide E.
155. Impeding the single-strand annealing pathway of DNA double-strand break repair by withaferin A-mediated FANCA degradation
156. In Vitro and In Vivo Cytotoxic Effects of withaferin A on Retinal Epithelial Pigmented Cells
157. In vitro propagation and withaferin A production in Withania ashwagandha, a rare medicinal plant of India
158. IN VITRO withaferin A PRODUCTION BY WITHANIA SOMNIFERA SUSPENSION CULTURE
159. In vivo growth inhibitory and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma
160. Increase of withaferin And a glutathione contents of Withania somnifera (L.) Dun. shoots cultivated in vitro on medium supplemented with Zn*[2+
161. Increased production of withanolide A, withanone, and withaferin A in hairy root cultures of Withania somnifera (L.) Dunal elicited with methyl jasmonate and salicylic …
162. INCREASING BIOMASS ACCUMULATION AND withaferin A PRODUCTION IN CELL SUSPENSION CULTURE OF WITHANIA SOMNIFERA
163. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation
164. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide withaferin A
165. Inhibition of inflammatory cytokine-induced response in human islet cells by withaferin A
166. Inhibition of monosodium urate crystal-induced inflammation by withaferin A
167. Inhibition of NFκB by the natural product withaferin A in cellular models of Cystic Fibrosis inflammation
168. Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera’s key metabolite withaferin A
169. Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera’s key metabolite withaferin A
170. Inhibitory effect of withaferin A on Helicobacter pylori‑induced IL‑8 production and NF‑κB activation in gastric epithelial cells
171. Insights from the predicted structural analysis of carborane substituted withaferin A with Indoleamine-2, 3-dioxygenase as a potent inhibitor
172. Integrated In silico Docking and MoMA Simulation Approaches Reveal withaferin A, Withalongolides A and B as Potent Aldo-Keto Reductase (AKR) 1C3 …
173. Interaction studies of Withania somnifera’s key metabolite withaferin A with different receptors associated with cardiovascular disease
174. Investigation of the role of withaferin A derivative in modulating signaling pathways in transformed cancer cells for inhibition of invasion and metastasis
175. ISOLATION AND CHARACTERIZATION OF WITHAFERIN-A FROM THE WITHANIA SOMNIFERA (ASHWAGANDHA)
176. Isolation and identification of withaferin A (Steroidal Lactone) from Withania somnifera (Ashwagandha).
177. Isolation of Withaferin-A from Withania Somnifera plant root and its effects on cancer rats
178. Lack of the cytochrome P450 3A interaction of methanolic extract of Withania somnifera, withaferin A, Withanolide A and Withanoside IV
179. L-Arginine abolishes the anxiolytic-like effect of withaferin A in the elevated plus-maze test in rats
180. LC-MS/MS method for the quantification of withaferin-Ain plant extracts of Withania spp.
181. Leaf ontogenic phase-related dynamics of withaferin A and withanone biogenesis in ashwagandha (Withania somnifera Dunal.)- an important medicinal herb
182. Ligand based virtual screening to identify potential anti cancer ligands similar to withaferin A targeting indoleamine 2, 3-dioxygenase
183. Lipopolysaccharides-stimulated macrophage products enhance withaferin A-induced apoptosis via activation of caspases and inhibition of NF-κB pathway in human …
184. Liquid chromatography-tandem mass spectrometry to assess the pharmacokinetics and tissue distribution of withaferin A in rats
185. Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells
186. Mechanistic elucidation of the antitumor properties of withaferin A in breast cancer
187. Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model
188. Metabolomics and proteomics reveal inhibition of glycolysis in withaferin A-mediated prevention of mammary carcinogenesis in MMTV-neu mice.
189. Microbial transformations of natural antitumor agents. 23. conversion of withaferin-A to 12β-and 15β-hydroxy derivatives of withaferin-A.
190. Microbial transformations of natural antitumor agents. 7. 14-alpha-Hydroxylation of withaferin-A by Cunninghamella elegans (NRRL 1393)
191. Microbiological and chemical dehydrogenation of withaferin A
192. Mild Thio‐Diversification of Bioactive Natural Products. withaferin A: A Case study.
193. Mitotic catastrophe and inhibition of growth of Castration Resistant Prostate Cancers by a dietary agent Withaferin-A.
194. Molecular conformations. Part VI. The structure of withaferin A: X-ray analysis of withaferin A acetate p-bromobenzoate
195. Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by withaferin A targeting indoleamine 2, 3 …
196. Molecular insight in the multifunctional activities of withaferin A
197. Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A
198. Molecular Insights Into Withaferin-A-Induced Senescence: Bioinformatics and Experimental Evidence to the Role of NFκB and CARF
199. Molecular mechanisms of hyperthermia-induced apoptosis enhanced by withaferin A
200. Molecular targets and mechanisms of cancer prevention and treatment by withaferin A, a naturally occurring steroidal lactone
201. Myeloid-derived suppressor cell function is reduced by withaferin A, a potent and abundant component of Withania somnifera root extract
202. Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I
203. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation
204. Neuroprotective Effect of CR-777, a Glutathione Derivative of withaferin A, Obtained through the Bioconversion of Withania somnifera (L.) Dunal Extract by the Fungus …
205. Neuroprotective efficacy of withaferin A on aging mediated oxidative stress in striatum and Substantia nigra of wistar albino rat.
206. Nf-κb-Dependent Inhibition of HIV-1 Transcription by withaferin A
207. Niosomal withaferin A with better antitumor efficacy
208. Nitrogen treatment enhances sterols and withaferin A through transcriptional activation of jasmonate pathway, WRKY transcription factors, and biosynthesis genes in …
209. Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A
210. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis
211. Novel cytotoxic and antitumor agents. IV. withaferin A: relation of its structure to the in vitro cytotoxic effects on P388 cells.
212. Novel validated HPTLC method for estimation of withaferin A in polyherbal formulations
213. On the action and mechanism of withaferin-A from Withania somnifera, a novel and potent melanin dispersing agent in frog melanophores
214. Optimisation of a microwave‐assisted method for extracting withaferin A from Withania somnifera Dunal. using central composite design
215. Optimization of Carbon Source for Hairy Root Growth and withaferin A and Withanone Production in Withania somnifera
216. Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model
217. Oral administration of Withaferin-A effectively suppresses prostate carcinogenesis in PTEN-Knockout mice
218. Overexpression of microRNA-25 by withaferin A induces cyclooxygenase-2 expression in rabbit articular chondrocytes
219. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway …
220. Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A
221. Par‐4 dependent modulation of cellular β‐catenin by medicinal plant natural product derivative 3‐azido withaferin A
222. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells
223. Pathological Evaluation of Anti-Tumour Effects of withaferin A against Experimentally Induced Mammary Tumour in Rats
224. PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells
225. Peptidyl‐prolyl cis/trans isomerase Pin1 regulates withaferin A‐mediated cell cycle arrest in human breast cancer cells
226. Pharmacogenomic Analysis of Adenylate Kinase-4 Gene Expression Signature Identifies Withaferin-A as an Anti-Metastatic Agent in Non-Small Cell Lung Cancer
227. Pharmacological and analytical aspects of withaferin A: A concise report of current scientific literature
228. Pharmacological levels of withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells
229. Pharmaological Control of Angiofibrosis by withaferin A
230. Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors
231. Pin1 is a novel target of withaferin A, a mammary cancer chemopreventative steroidal lactone from Withania somnifera
232. Piriformospora indica elicitation of withaferin A biosynthesis and biomass accumulation in cell suspension cultures of Withania somnifera
233. PO-293 Withaferin-A: a candidate anti-tumour natural compound for non-small cell lung cancer and stem cells
234. Possible nitric oxide modulation in protective effects of withaferin A against stress induced neurobehavioural changes
235. Potent Anti-Fibrotic Activity of withaferin A in Ocular Injury Models
236. Potential Angiopreventive Mode of Action of withaferin A
237. Preliminary Study on the Synthesis of withaferin A.
238. Prevention of articular cartilage degeneration in a rat model of monosodium iodoacetate induced osteoarthritis by oral treatment with withaferin A
239. Prevention of mammary carcinogenesis and pulmonary metastasis by Ayurvedic medicine constituent withaferin A in a clinically-relevant transgenic mouse model.
240. Preventive effects of withaferin A isolated from the leaves of an Indian medicinal plant Withania somnifera (L.): comparisons with 17-β-estradiol and alendronate
241. Probing the anticancer mechanism of prospective herbal drug withaferin A on mammals: a case study on human and bovine proteasomes
242. Production dynamics of withaferin A in Withania somnifera (L.) Dunal complex
243. Production of reactive oxygen species by withaferin A causes loss of type collagen expression and COX-2 expression through the PI3K/Akt, p38, and JNK pathways in …
244. Production of the Anticancer Compound withaferin A from Genetically Transformed Hairy Root Cultures of Withania Somnifera
245. Production of withaferin A in shoot cultures of Withania somnifera
246. Proinflammatory cytokines IL-6 and TNF-α increased telomerase activity through NF-κB/STAT1/STAT3 activation, and withaferin A inhibited the signaling in colorectal …
247. Protection against cerebral infarction by withaferin A involves inhibition of neuronal apoptosis, activation of PI3K/Akt signaling pathway, and reduced intimal …
248. Protective effect of Withaferin-A on micronucleus frequency and detoxication agents during experimental oral carcinogenesis
249. Protective effect of Withaferin-A on tumour formation in 7, 12-dimethylbenz [a] anthracene induced oral carcinogenesis in hamsters
250. Protective Effect Of Withania Somnifera And Its Active Component withaferin A In Bromobenzene Induced Hepato And Nephrotoxicity
251. Protective role of withaferin‐A on 7, 12‐dimethylbenz (a) anthracene‐induced genotoxicity in bone marrow of Syrian golden hamsters
252. Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7, 12-dimethylbenz (a) anthracene-induced experimental oral carcinogenesis
253. Protective role of Withaferin-A on red blood cell integrity during 7, 12-dimethylbenz [a] anthracene induced oral carcinogenesis
254. Proteomic characterization of withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies
255. Quantification of withaferin-A and withanolide-A in diploid (n = 12) and tetraploid cytotypes (n = 24) of “Rassbhary”, Physalis angulata L
256. Radiosensitization of a mouse melanoma by withaferin A: In vivo studies
257. Radiosensitizing effect of withaferin A combined with hyperthermia on mouse fibrosarcoma and melanoma
258. Rapid and sensitive method for determination of withaferin-A in human plasma by HPLC
259. Reactions of withaferin-A with model biological nucleophiles
260. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine
261. Regiospecific Synthesis of Ring A Fused withaferin A Isoxazoline Analogues: Induction of Premature Senescence by W-2b in Proliferating Cancer Cells
262. Relationship between chemical structure and antitumor activity of withaferin A analogues
263. Response of a mouse fibrosarcoma to withaferin A and radiation
264. Response Surface Optimization Of In Vitro Culture Medium For Enhanced Production Of The Therapeutically Important Secondary Metabolite–withaferin A
265. Ring A structural modified derivatives of withaferin A and the evaluation of their cytotoxic potential
266. Role of mitogen‐activated protein kinases and Mcl‐1 in apoptosis induction by withaferin A in human breast cancer cells
267. Role of withaferin A as a Neuroprotectant against Beta Amyloid Induced Toxicity and associated mechanism
268. RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF WITHAFERIN-A IN RANGER CAPSULE
269. Safety and Pharmacokinetics of Withaferin-A in advanced stage high grade Osteosarcoma: A phase I trial
270. Safety assessment of Withania somnifera extract standardized for withaferin A: acute and sub-acute toxicity study
271. Scientific Evidence for Anticancer Effects of Withania somnifera and Its Primary Bioactive Component withaferin A
272. Selective cytotoxicity of non-small cell lung cancer cells by the withaferin A-fortified root extract of Ashwagandha involves differential cell-cycle arrest and …
273. Semi-synthesis of a novel hybrid isoxazolidino withaferin via chemoselective and diastereoselective 1, 3-dipolar nitrone cycloaddition reaction
274. Semi-synthetic approach of withaferin A: Related steroidal lactones as a potent anti proliferative agents
275. Simultaneous estimation of guggulsterone E, guggulsterone Z, KBA, AKBA, withaferin A and 6-gingerol by using HPLC-DAD method from ariflex tablet …
276. Simultaneous Estimation of Stigmasterol and withaferin A in Union Total Herbal Formulation Using Validated HPTLC Method
277. Simultaneous Estimation of withaferin A and Z-Guggulsterone in Marketed Formulation by RP-HPLC
278. Simultaneous High-Performance Thin-Layer Chromatographic Quantification of withaferin A and Withanolide A in Solanum nigrum L. “Black Nightshade”
279. STAT3 inhibitory activity of structurally simplified withaferin A analogues
280. Stress induced somatic embryogenesis: an alternative technique to enhance production of withaferin A in Indian ginseng (Withania somnifera L.) Dunal
281. Structure-based design of new analogs of withaferin A as antitumor agents
282. Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers
283. Studies on oral bioavailability and first‐pass metabolism of withaferin A in rats using LC–MS/MS and Q‐TRAP
284. Study on the Anticarcinogenic Efficacy of Withaferin-A in DEN Induced Hepatocellular Carcinoma: Morphology and Histopathology
285. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human …
286. Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines
287. Synergistic inhibition of glioma cell proliferation by withaferin A and tumor treating fields
288. Synthetic studies of withanolide I Synthesis of AB ring moiety of withaferin A
289. Targeting glioblastoma stem cells with withaferin A
290. Targeting Her-2/neu breast cancers with a plant derived natural compound, withaferin A (53.15)
291. Targeting NFκB and MAP Kinases in Pancreatic Beta Cells to Suppress Islet Inflammation By withaferin A.: Abstract# C1727
292. Targeting RAW 264.7 macrophages (M1 type) with Withaferin-A decorated mannosylated liposomes induces repolarization via downregulation of NF-κB and …
293. The Anti-Angiogenic Activity of withaferin A Is Mediated by the Intermediate Filament Protein Vimentin
294. The chemopreventive effect of withaferin A on spontaneous and inflammation-associated colon carcinogenesis models
295. The effect of withaferin A on human peripheral blood lymphocytes: An electron-microscope study
296. The effect of withaferin A on plant cells
297. The effect of withaferin A, a natural steroidal lactone, on the fine structure of S-180 tumor cells
298. The Effects of withaferin A on Normal and Malignant Immune Cells
299. The glucose metabolism targeting therapies and withaferin A eliminate epidermal growth factor tyrosine kinase inhibitor-induced drug-tolerant persisters in non-small …
300. The inhibitory effect of withaferin A on the growth of orthotopic xenograft tumor of hepatocellular carcinoma in nude mice and the mechanism
301. The Natural Compound withaferin A Covalently Binds to Cys239 of β-Tubulin to Promote Tubulin Degradation
302. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin
303. The tumor proteasome is a primary target for the natural anticancer compound withaferin A isolated from “Indian winter cherry”
304. The use of withaferin A to study intermediate filaments
305. Therapeutic relevance of withaferin-A induced apoptotic and autophagic regulation in human cancer cell-lines
306. Thiol dependent NF-κB suppression and inhibition of T-cell mediated adaptive immune responses by a naturally occurring steroidal lactone withaferin A
307. To check the glioprotective effect of withaferin A on C6 Glioma cell Culture challenged with Kainic Acid
308. To Test The Role Of withaferin A In Neuroprotection On Sh-Sy5Y Cell Line Challenged By Kainic Acid
309. Towards Therapeutic Chemical Genetics: Polypharmacology of withaferin A on Corneal Angiogenesis and Retinal Gliosis is Mediated by Type III Intermediate …
310. Treatment of adult and pediatric high-grade gliomas with withaferin A: antitumor mechanisms and future perspectives
311. Tumor inhibitors. XXXIX. Active principles of Acnistur arborescens. Isolation and structural and spectral studies of withaferin A and withacnistin
312. Tumor Size Reduction With withaferin A In A Murine Model Of Uveal Melanoma
313. Validated HPLC method development for simultaneous analysis of withaferin-A and 6-gingerol
314. Vassobia breviflora root-extract withaferin A as a novel cytotoxic and synergistic agent against malignant gliomas
315. Vimentin and Glial Fibrillar Acidic Protein are Targeted by withaferin A in Retinal Gliosis
316. Vimentin Phosphorylation Underlies Corneal Myofibroblast Sensitivity to withaferin A
317. Vimentin phosphorylation underlies myofibroblast sensitivity to withaferin A in vitro and during corneal fibrosis
318. Water-soluble withaferin A polymer prodrugs via a drug-functionalized RAFT CTA approach
319. withaferin A
320. withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells
321. withaferin A abolishes the stem cell factor-stimulated pigmentation of human epidermal equivalents by interrupting the auto-phosphorylation of c-KIT in human …
322. withaferin A activates stress signalling proteins in high risk acute lymphoblastic leukemia
323. withaferin A activity against glioblastoma cells: Supression of microtubule dynamics
324. withaferin A alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells
325. withaferin A alters intermediate filament organization, cell shape and behavior
326. withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling
327. withaferin A ameliorates renal injury due to its potent effect on inflammatory signaling
328. withaferin A analogs that target the AAA+ chaperone p97
329. withaferin A analogues up-regulate the MAPK and glutathione metabolic pathways prior to activation of apoptosis in pancreatic cancer cells
330. withaferin A and its potential role in glioblastoma (GBM)
331. withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms
332. withaferin A and tumor treating fields synergistically inhibit glioma proliferation
333. withaferin A and Withanolide D analogues with dual heat-shock-inducing and cytotoxic activities: semisynthesis and biological evaluation
334. withaferin A associated differential regulation of inflammatory cytokines
335. withaferin A attenuates Alcohol Abstinence Signs in Rats
336. withaferin A attenuates bleomycin‐induced scleroderma by targeting FoxO3a and NF‐κβ signaling: Connecting fibrosis and inflammation
337. withaferin A attenuates lipopolysaccharide-induced acute lung injury in neonatal rats.
338. withaferin A Attenuates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Death Cascade Blockade in an AMPK Dependent Manner
339. withaferin A attenuates ovalbumin induced airway inflammation
340. withaferin A binds covalently to the N-terminal domain of annexin A2
341. withaferin A blocks formation of IFN-γ-induced metastatic cancer stem cells through inhibition of the CXCR4/CXCL12 pathway in the UP-LN1 carcinoma cell model
342. withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells
343. withaferin A causes autophagy in normal as well as cancerous human breast cells
344. withaferin A causes FOXO3a-and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo
345. withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling
346. withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial …
347. withaferin A downregulates tubulins and covalently binds β-tubulin at cysteine-303 in human breast cancer cells
348. withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis
349. withaferin A enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition
350. withaferin A exerts anti-tumor effects in gliobIastoma cells by arresting cell cycle at G2/M phase
351. withaferin A from cell cultures of Withania somnifera
352. withaferin A Improves Nonalcoholic Steatohepatitis in Mice
353. withaferin A in combination with cisplatin targets CD44 and Oct4 positive cancer stem cells in ovarian cancer
354. withaferin A induced impaired autophagy and unfolded protein response in human breast cancer cell-lines MCF-7 and MDA-MB-231
355. withaferin A induces apoptosis and inhibits adipogenesis in 3T3‐L1 adipocytes
356. withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through …
357. withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells
358. withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2
359. withaferin A induces apoptosis in rat C6 glioma cells through regulating NF-ΚB nuclear translocation and activation of caspase cascade
360. withaferin A induces apoptosis through the generation of thiol oxidation in human head and neck cancer cells
361. withaferin A induces cell death and differentiation in multiple myeloma cancer stem cells
362. withaferin A induces cell death selectively in androgen-independent prostate cancer cells but not in normal fibroblast cells
363. withaferin A induces cytoprotective autophagy in hepatocellular cancer cells and concomitant autophagic inhibition augments the efficacy of withaferin A in …
364. withaferin A induces heme oxygenase (HO-1) expression in endothelial cells via activation of the Keap1/Nrf2 pathway
365. withaferin A induces mitochondrial-dependent apoptosis in non-small cell lung cancer cells via generation of reactive oxygen species.
366. withaferin A induces nonprotective autophagy in a STK11-independent manner and mediates breast cancer inhibition via energetic impairment
367. withaferin A induces Nrf2-dependent protection against liver injury: role of Keap1-independent mechanisms
368. withaferin A induces oxidative stress-mediated apoptosis and DNA damage in oral cancer cells
369. withaferin A Induces p27Kip1 Expression to Inhibit Corneal Angio-Fibrosis
370. withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells
371. withaferin A induces proteasome inhibition, endoplasmic reticulum stress, the heat shock response and acquisition of thermotolerance
372. withaferin A induces proteasome-dependent degradation of breast cancer susceptibility gene 1 and heat shock factor 1 proteins in breast cancer cells
373. withaferin A induces ROS-mediated paraptosis in human breast cancer cell-lines MCF-7 and MDA-MB-231
374. withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells
375. withaferin A inhibits adipogenesis in 3T3-F442A cell line, improves insulin sensitivity and promotes weight loss in high fat diet-induced obese mice
376. withaferin A inhibits apoptosis via activated Akt-mediated inhibition of oxidative stress
377. withaferin A inhibits breast cancer invasion and metastasis at sub‐cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation
378. withaferin A inhibits epithelial to mesenchymal transition in non-small cell lung cancer cells
379. withaferin A inhibits epithelial-to-mesenchymal transition in non-small lung cell cancer cells via regulation of SMAD and NFkB signaling
380. withaferin A inhibits experimental epithelial–mesenchymal transition in MCF‐10A cells and suppresses vimentin protein level in vivo in breast tumors
381. withaferin A inhibits expression of ataxia telangiectasia and Rad3‐related kinase and enhances sensitivity of human breast cancer cells to cisplatin
382. withaferin A inhibits helicobacter pylori-induced production of IL-1β in dendritic cells by regulating NF-κB and NLRP3 inflammasome activation
383. withaferin A inhibits hepatoma cell proliferation through induction of apoptosis and cell cycle arrest
384. withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown
385. withaferin A inhibits inflammatory responses induced by Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans in macrophages
386. withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-κB in RAW 264.7 cells
387. withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells
388. withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells
389. withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway
390. withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ
391. withaferin A inhibits nuclear factor-κB-dependent pro-inflammatory and stress response pathways in the astrocytes
392. withaferin A inhibits osteosarcoma cells through inactivation of Notch-1 signalling
393. withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation
394. withaferin A inhibits prostate carcinogenesis in a PTEN-deficient mouse model of prostate cancer
395. withaferin A inhibits STAT3 and induces tumor cell death in neuroblastoma and multiple myeloma
396. withaferin A inhibits the malignant pleural mesothelioma growth in vitro and in vivo
397. withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis
398. withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo
399. withaferin A inhibits tumor necrosis factor-α-induced expression of cell adhesion molecules by inactivation of Akt and NF-κB in human pulmonary epithelial cells
400. withaferin A Is a Chemical Genetic Probe of the Intermediate Filament Protein Vimentin
401. withaferin A is a leptin sensitizer with strong antidiabetic properties in mice
402. withaferin A is a potent inhibitor of angiogenesis
403. withaferin A is an inhibitor of endothelial protein C receptor shedding in vitro and in vivo
404. withaferin A is effective in inhibiting the survival of B cell lymphomas and chronic lymphocytic leukemias (P2052)
405. withaferin A modulates AIM2 inflammasome and caspase-1 expression in THP-1 polarized macrophages
406. withaferin A modulates the Spindle Assembly Checkpoint by degradation of Mad2–Cdc20 complex in colorectal cancer cell lines
407. withaferin A Prevents Myocardial Ischemia/Reperfusion Injury by Upregulating AMP-Activated Protein Kinase-Dependent B-Cell Lymphoma2 Signaling
408. withaferin A Production by Root Cultures of Withania coagulans
409. withaferin A promotes proliferation and migration of brain endothelial cells
410. withaferin A Protects Against High-Fat Diet–Induced Obesity Via Attenuation of Oxidative Stress, Inflammation, and Insulin Resistance
411. withaferin A protects against palmitic acid-induced endothelial insulin resistance and dysfunction through suppression of oxidative stress and inflammation
412. withaferin A protects against spinal cord injury by inhibiting apoptosis and inflammation in mice
413. withaferin A regulates LRRK2 levels by interfering with the Hsp90-Cdc37 chaperone complex
414. withaferin A Regulates Muller Glial Cell Cycle During Retinal Gliosis
415. withaferin A reverses bile duct ligation‐induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2/Snail1, vimentin, and NFκB signaling
416. withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP
417. withaferin A strongly elicits IκB kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity
418. withaferin A suppresses and inhibits hepatocellular carcinoma-cell proliferation and tumor burden via activation of ERK1/2-ELK1-RSK-DR5 axis
419. withaferin A suppresses anti-apoptotic BCL2, Bcl-xL, XIAP and Survivin genes in cervical carcinoma cells
420. withaferin A suppresses Beta amyloid in APP expressing cells: Studies for Tat and Cocaine associated neurological dysfunctions
421. withaferin A suppresses estrogen receptor‐α expression in human breast cancer cells
422. withaferin A suppresses liver tumor growth in a nude mouse model by downregulation of cell signaling pathway leading to invasion and angiogenesis
423. withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor
424. withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression